Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
US Army
Fuji
Chinese Patent Office
Medtronic
Harvard Business School
UBS
Healthtrust
Mallinckrodt
Novartis

Generated: October 18, 2017

DrugPatentWatch Database Preview

Valeant Bermuda Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT BERMUDA, and when can generic versions of VALEANT BERMUDA drugs launch?

VALEANT BERMUDA has eight approved drugs.

There are five US patents protecting VALEANT BERMUDA drugs.

There are eighty-eight patent family members on VALEANT BERMUDA drugs in thirty-six countries and twenty-four supplementary protection certificates in twelve countries.

Summary for Applicant: Valeant Bermuda

International Patents:88
US Patents:5
Tradenames:7
Ingredients:7
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Bermuda
BENZACLIN
benzoyl peroxide; clindamycin phosphate
GEL;TOPICAL050756-002Apr 20, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Bermuda
ELIDEL
pimecrolimus
CREAM;TOPICAL021302-001Dec 13, 2001RXYesYes► Subscribe► SubscribeY► Subscribe
Valeant Bermuda
BENZACLIN
benzoyl peroxide; clindamycin phosphate
GEL;TOPICAL050756-001Dec 21, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Bermuda
ZOVIRAX
acyclovir
OINTMENT;TOPICAL018604-001Mar 29, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982AB1RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Bermuda
ELIDEL
pimecrolimus
CREAM;TOPICAL021302-001Dec 13, 2001RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Bermuda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Bermuda
ZOVIRAX
acyclovir
OINTMENT;TOPICAL018604-001Mar 29, 1982► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL019049-001Sep 16, 1988► Subscribe► Subscribe
Valeant Bermuda
ELIDEL
pimecrolimus
CREAM;TOPICAL021302-001Dec 13, 2001► Subscribe► Subscribe
Valeant Bermuda
PENLAC
ciclopirox
SOLUTION;TOPICAL021022-001Dec 17, 1999► Subscribe► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009► Subscribe► Subscribe
Valeant Bermuda
DERMATOP E EMOLLIENT
prednicarbate
CREAM;TOPICAL020279-001Oct 29, 1993► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL019049-001Sep 16, 1988► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant Bermuda
ELIDEL
pimecrolimus
CREAM;TOPICAL021302-001Dec 13, 2001► Subscribe► Subscribe
Valeant Bermuda
RETIN-A
tretinoin
CREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Valeant Bermuda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,337,324 Pharmaceutical combination► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Bermuda Drugs

Country Document Number Estimated Expiration
South Africa9700608► Subscribe
China1326364► Subscribe
Norway316355► Subscribe
Australia4682196► Subscribe
World Intellectual Property Organization (WIPO)0029027► Subscribe
Hong Kong1042440► Subscribe
South Africa9600527► Subscribe
Brazil9707304► Subscribe
Israel116913► Subscribe
Austria288283► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Bermuda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90049-3Sweden► SubscribePRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
C/GB11/054United Kingdom► SubscribePRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
172Luxembourg► SubscribePRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
00097Netherlands► SubscribePRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
00043Netherlands► SubscribePRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
C/GB05/029United Kingdom► SubscribePRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218
/2001Austria► SubscribePRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Citi
Chinese Patent Office
Novartis
US Army
Cipla
Argus Health
Fish and Richardson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot